X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (448) 448
Publication (36) 36
Book Chapter (9) 9
Book Review (7) 7
Web Resource (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (294) 294
oncology (250) 250
lung neoplasms - drug therapy (218) 218
carcinoma, non-small-cell lung - drug therapy (199) 199
index medicus (159) 159
chemotherapy (155) 155
aged (143) 143
female (118) 118
male (118) 118
lung neoplasms - pathology (112) 112
antineoplastic combined chemotherapy protocols - therapeutic use (97) 97
antineoplastic agents - therapeutic use (92) 92
middle aged (91) 91
carcinoma, non-small-cell lung - pathology (87) 87
nsclc (83) 83
cancer (77) 77
adult (67) 67
respiratory system (66) 66
hematology, oncology and palliative medicine (63) 63
treatment outcome (58) 58
lung cancer, non-small cell (55) 55
aged, 80 and over (52) 52
care and treatment (49) 49
lung neoplasms - mortality (48) 48
neoplasm staging (48) 48
cisplatin (47) 47
therapy (47) 47
erlotinib (46) 46
lung cancer (45) 45
cisplatin - administration & dosage (44) 44
pulmonary/respiratory (44) 44
gefitinib (42) 42
gemcitabine (42) 42
carcinoma, non-small-cell lung - mortality (41) 41
carboplatin (40) 40
docetaxel (40) 40
survival (40) 40
non-small cell lung cancer (39) 39
bevacizumab (38) 38
antineoplastic combined chemotherapy protocols - adverse effects (37) 37
open-label (37) 37
phase-iii trial (37) 37
deoxycytidine - analogs & derivatives (36) 36
pemetrexed (36) 36
quality of life (36) 36
vinorelbine (35) 35
clinical trials as topic (34) 34
paclitaxel (34) 34
lung neoplasms - genetics (33) 33
pharmacology & pharmacy (33) 33
protein kinase inhibitors - therapeutic use (33) 33
trial (32) 32
carcinoma, non-small-cell lung - genetics (31) 31
elderly (31) 31
receptor, epidermal growth factor - antagonists & inhibitors (31) 31
targeted therapy (30) 30
disease-free survival (29) 29
prognosis (29) 29
randomized controlled trials as topic (28) 28
vinblastine - analogs & derivatives (28) 28
combination (27) 27
deoxycytidine - administration & dosage (26) 26
immunotherapy (26) 26
quality-of-life (26) 26
survival rate (26) 26
antineoplastic agents - adverse effects (25) 25
clinical-trials (25) 25
egfr (25) 25
survival analysis (25) 25
age factors (24) 24
clinical trials (24) 24
mutation (24) 24
antibodies, monoclonal - therapeutic use (23) 23
cell lung-cancer (23) 23
vinblastine - administration & dosage (23) 23
animals (22) 22
antineoplastic agents - pharmacology (22) 22
carcinoma (21) 21
guanine - analogs & derivatives (21) 21
randomized-trial (21) 21
erlotinib hydrochloride (20) 20
growth-factor receptor (20) 20
phase-ii trial (20) 20
1st-line treatment (19) 19
advanced nsclc (19) 19
double-blind (19) 19
lung neoplasms - therapy (19) 19
nivolumab (19) 19
antitumor-activity (18) 18
cancer therapies (18) 18
disease progression (18) 18
non-small-cell lung cancer (18) 18
quinazolines - therapeutic use (18) 18
carcinoma, non-small-cell lung - therapy (17) 17
drug administration schedule (17) 17
elderly-patients (17) 17
italy (17) 17
phase-iii (17) 17
crizotinib (16) 16
elderly patients (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 247 - 255
Journal Article
The Oncologist, ISSN 1083-7159, 02/2001, Volume 6, Issue 1, pp. 4 - 7
In a phase III trial, 191 patients aged over 70 with stage IIIB/IV non‐small cell lung cancer were randomized to receive best supportive care (BSC) alone or... 
ELVIS | Best Supportive Care | Vinorelbine | Best supportive care | vinorelbine | best supportive care | CISPLATIN | ONCOLOGY
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 55 - 63
Journal Article
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4774, 09/2013, Volume 10, Issue 9, p. 490
The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of... 
Lung Neoplasms - diagnosis | Humans | Carcinoma, Non-Small-Cell Lung - diagnosis
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 08/2012, Volume 9, Issue 8, pp. 434 - 435
Treatment of locally advanced non-small-cell lung cancer (NSCLC) in the elderly is challenging, with many available treatment options from radiotherapy alone... 
SURVIVAL | THERAPY | NSCLC | ONCOLOGY | Carcinoma, Non-Small-Cell Lung - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Aged | Clinical Trials as Topic | Combined Modality Therapy | Lung Neoplasms - therapy | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2895 - 2902
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 09/2013, Volume 10, Issue 9, pp. 490 - 492
The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of... 
Chemotherapy | Care and treatment | Lung cancer, Non-small cell | Health aspects | Patient outcomes | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1254 - 1262
Journal Article
Expert Opinion on Emerging Drugs, ISSN 1472-8214, 10/2019, Volume 24, Issue 4, pp. 233 - 237
Introduction: Metastatic renal cell carcinoma (mRCC) in recent years has been one of the diseases in the oncology that has experienced the greatest development... 
Renal cell carcinoma | PD-1 | immunocheckpoint inhibitors | immunotherapy
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2018, Volume 15, Issue 10, pp. 593 - 594
Platinum-based chemotherapy has long been the mainstay first-line therapy for patients with non-small-cell lung cancer without a targetable driver mutation,... 
Antibodies, Monoclonal, Humanized | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Humans | Immunotherapy | Chemotherapy | Care and treatment | Patient outcomes | Development and progression | Lung cancer, Non-small cell | Methods | Cancer | Non-small cell lung carcinoma | Health risk assessment | Platinum
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article